NCT06329947View on ClinicalTrials.gov

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

September 30, 2026

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Surufatinib 250mg/d qd once daily

mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.

Trial Locations (1)

Unknown

SunYat-senUniversity Cancer Center, Guangzhou

All Listed Sponsors
lead

Rui-hua Xu, MD, PhD

OTHER

NCT06329947 - A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | Biotech Hunter | Biotech Hunter